Clinical Trial Update: Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sacituzumab govitecan before radical cystectomy for non-urothelial muscle invasive bladder cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: University of Washington | Conditions: Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Status: RECRUITING